F
Faqian Bu
Researcher at Sichuan University
Publications - 10
Citations - 93
Faqian Bu is an academic researcher from Sichuan University. The author has contributed to research in topics: Chemistry & Medicine. The author has an hindex of 2, co-authored 4 publications receiving 4 citations.
Papers
More filters
Journal ArticleDOI
Recent Progress on Tubulin Inhibitors with Dual Targeting Capabilities for Cancer Therapy.
Wen Shuai,Guan Wang,Yiwen Zhang,Faqian Bu,Sicheng Zhang,Duane D. Miller,Wei Li,Liang Ouyang,Yuxi Wang +8 more
TL;DR: In this paper, the authors discussed rational target combinations, design strategies, structure-activity relationships, and future directions of dual-target tubulin inhibitors, and proposed a new approach to overcome drug resistance and dose-limiting toxicity.
Journal ArticleDOI
Developing potent LC3-targeting AUTAC tools for protein degradation with selective autophagy.
Junping Pei,Xiaoli Pan,Aoxue Wang,Wen Shuai,Faqian Bu,Pan Tang,Shuai Zhang,Yiwen Zhang,Guan Wang,Liang Ouyang +9 more
TL;DR: In this article, a novel type of autophagy-targeting chimera (AUTAC) was used to degrade protein by targeting autophag key protein LC3, and the best compound 10f powerfully degraded BRD4 protein through the autophage pathway and exhibited good anti-proliferative activity in multiple tumor cells.
Journal ArticleDOI
Development of small molecule extracellular signal-regulated kinases (ERKs) inhibitors for cancer therapy
Xiaoli Pan,Junping Pei,Aoxue Wang,Wen Shuai,Lu Feng,Faqian Bu,Yumeng Zhu,Lan Zhang,Guan Wang,Liang Ouyang +9 more
TL;DR: In this article , the authors provide an overview of the physiological and biological functions of ERKs, focusing on the structure-activity relationships of small molecule inhibitors targeting ERK, with a view to providing guidance for future drug design and optimization, and discusses the potential therapeutic strategies to overcome drug resistance.
Journal ArticleDOI
Discovery of Tyrosinase Inhibitors: Structure-Based Virtual Screening and Biological Evaluation
TL;DR: T1 and T5 may represent the promising drug candidates for hyperpigmentation therapy in pharmaceutical fields, as well as the effective whitening agents in cosmetic applications.
Journal ArticleDOI
Repurposing drugs in autophagy for the treatment of cancer: From bench to bedside.
TL;DR: In this paper, the authors describe the application of different drug-repurposing approaches in autophagy for the treatment of cancer and focus on repurposing drugs that target autophathy to treat malignant neoplasms.